×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABVX – abivax sa - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABVX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/24
09:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/7
06:19 am
abvx
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/5
07:02 pm
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
11/4
07:21 am
abvx
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/3
04:05 pm
abvx
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
Low
Report
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
10/13
07:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $142.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) was given a new $142.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/10
07:19 am
abvx
Abivax (NASDAQ:ABVX) was given a new $150.00 price target on by analysts at Guggenheim.
Low
Report
Abivax (NASDAQ:ABVX) was given a new $150.00 price target on by analysts at Guggenheim.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: